ABT — Q2 2026 Financial Report Analysis
Q2 · Fiscal year 2026 · Published by Pham Hop · AI-drafted from the SEC filing
Reported sales grew 13.0% but organic growth was 4.8%; the Exact Sciences acquisition drives most of the gap, and $658M of quarterly intangible amortization plus a $385M litigation reserve explain why GAAP EPS ($0.53) is less than half of adjusted EPS ($1.31).
Overview
Abbott's reported sales grew 13.0% in the second quarter, but comparable (organic) sales growth was 4.8% — the difference is mostly the Exact Sciences acquisition, which closed March 23, 2026 and is included in reported sales but excluded from the comparable figure, plus the roll-off of a competitor compensation payment to the Structural Heart business that ended in Q1 2026. GAAP diluted EPS was $0.53 versus adjusted diluted EPS of $1.31. This is not a one-time distortion: the $0.78 per share gap is $658 million of intangible amortization (a recurring cost of Abbott's acquisition-heavy business model, not a one-off) plus a $385 million legal reserve for an agreed-in-principle settlement and smaller acquisition-integration and restructuring costs.
Key Financial Metrics
| Metric | Q2 2026 | YoY Change |
|---|---|---|
| Total sales (reported) | $12,593M | +13.0% |
| Comparable (organic) sales growth | — | +4.8% |
| GAAP diluted EPS | $0.53 | — |
| Adjusted diluted EPS | $1.31 | — |
| Capital returned to shareholders | $2.1B | — |
The release states quarterly sales growth rates rather than restating prior-year dollar figures alongside them, and does not give a year-over-year comparison for GAAP/adjusted EPS in the headline results — only the current-quarter values above.
Takeaway: The $658 million of quarterly intangible amortization is a structural, recurring feature of Abbott's results, not an unusual one-time item — it reflects continuous acquisition activity (most recently Exact Sciences) and will keep suppressing GAAP EPS relative to adjusted EPS in future quarters by a similar magnitude, independent of operating performance.
Segment Detail
Medical Devices, Abbott's largest segment, grew 9.0% reported and 8.4% comparable — the most consistent segment this quarter, with growth described as broad-based rather than tied to one product. Diagnostics grew 42.3% reported but only 2.9% comparable, meaning almost all of the reported Diagnostics growth is the Exact Sciences acquisition rather than the existing diagnostics business. Established Pharmaceuticals grew 8.4% (both reported and comparable, an international-only segment). Nutrition sales declined 3.1% reported and 3.6% comparable, which the company attributes to lower sales volumes and the effect of pricing actions taken in Q4 2025 creating a difficult year-over-year comparison; Nutrition sales did increase $127 million sequentially versus Q1 2026, indicating the segment is recovering within the year even though the year-over-year comparison is still negative.
Capital Allocation
Abbott returned $2.1 billion to shareholders in the quarter through dividends and share repurchases.
Outlook
Abbott reaffirmed full-year 2026 comparable sales growth guidance of 6.5% to 7.5% and raised full-year adjusted diluted EPS guidance to $5.45-$5.60 (from $5.38-$5.58). Management's stated expectation is for sales and earnings growth to accelerate in the second half of 2026 relative to the first half; the Nutrition segment's sequential improvement and the Exact Sciences integration are the two most direct things to check against that expectation in the next quarter's results.
More Abbott Laboratories reports
Recent in Health Care
- IQVIA (IQV) · Q2 2026Revenue $4.4B (+8.7%) · EPS $1.53 (-0.6%)
IQVIA revenue rose 8.7% to $4.37B with both segments widening margins and a record $3.15B of R&D bookings (1.22x book-to-bill), but higher restructuring, stock pay, interest and tax left GAAP EPS at $1.53 vs $1.54; full-year guidance raised.
- Insulet Corporation (PODD) · Q2 2026Revenue $802M (+23.5%) · EPS $1.37 (+328.1%)
Insulet grew Q2 revenue 23.5% to $801.7M and beat its guidance, but cut its full-year U.S. Omnipod growth outlook to 17%-19%, citing what it is learning in type 2 diabetes, while pod-correction costs weighed on GAAP margins.
- Incyte (INCY) · Q2 2026Revenue $1.7B (+37.7%) · EPS $2.81 (+37.7%)
Incyte's Q2 2026 revenue rose 37.7% to $1.67B, lifted by a $246M one-time Opzelura Medicaid-rebate reversal; excluding it, net sales grew 17% as Jakafi rose 7% and newer drugs jumped 69%, and full-year sales guidance was raised to $5.13–5.26B.